Illumina: Q2 Earnings Insights


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Shares of Illumina (NASDAQ:ILMN) moved lower in after-market trading after the company reported Q2 results.

Quarterly Results

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Earnings per share were up 201.61% over the past year to $1.87, which beat the estimate of $1.35.

Revenue of $1,126,000,000 up by 77.88% year over year, which beat the estimate of $1,010,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $6.30 and $6.50.

The upcoming fiscal year's revenue expected to be between $4,275,000,000 and $4,340,000,000.

Details Of The Call


Want Private Access to Benzinga Analyst?

Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.


Date: Aug 05, 2021

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.illumina.com%2F&eventid=3193061&sessionid=1&key=77F2A401A8737539C9DD57C2F340E743®Tag=&V2=false&sourcepage=register

Technicals

52-week high: $555.77

52-week low: $260.42

Price action over last quarter: Up 28.35%

Company Description

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: EarningsBZI-Recaps